Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Published in Critical Care Medicine, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a...